Atalanta Therapeutics

Biotech · Private

Multi-siRNA RNAi platform delivering multiple silencing RNAs targeting neurological and liver diseases

atalantarx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
40
0 granted · 40 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1636Amplifier Therapeutics——
1637Rapt Therapeutics—$303M
1638SAPPHIRE BIOTECH, INC.——
1639Atalanta Therapeutics——
1640Aera Therapeutics——
1641LIGANDOMICSRX, LLC——
1642DOPHEN BIOMED, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 40
  • siRNA COMPOSITIONS AND METHODS TARGETING ALPHA-SYNUCLEIN NUCLEIC ACIDSapplication
  • Compositions And Methods For Treatment Of Spinocerebellar Ataxiasapplication
  • Compositions And Methods For Treatment Of Neuroinflammatory Diseasesapplication
  • Compositions And Methods For Treatment Of Neurological Disordersapplication
  • Compositions And Methods For Treatment Of Microsatellite Dna Expansion Disordersapplication
  • Compositions And Methods For Treatment Of Prion Diseasesapplication
  • Noncovalently Branched Oligonucleotide Compositionsapplication
  • Compositions And Methods For Treatment Of Painapplication
  • Compositions And Methods For Delivering Therapeutic Oligonucleotides To The Central Nervous Systemapplication
  • Microglial Gene Silencing Using Double-stranded Sirnaapplication
  • Double-stranded Sirna Having Patterned Chemical Modificationsapplication
  • Compositions And Methods For Treatment Of Microsatellite Dna Expansion Disordersapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.